Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin–aldosterone–angiotensin system inhibitors in patients with chronic myelogenous leukemia

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, TKI-related chronic renal toxicity has been reported, particularly in patients with hypertension. We assessed whether incidental use of specific types of antihypertensive drugs, including...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2022-12, Vol.116 (6), p.863-870
Main Authors: Tsuda, Mariko, Hirata, Akie, Tokunaga, Shoji, Masuda, Toru, Haji, Shojiro, Kimura, Daisaku, Nojiri, Chinatsu, Nakashima, Yasuhiro, Shiratsuchi, Motoaki, Kato, Koji, Miyamoto, Toshihiro, Akashi, Koichi, Nakashima, Naoki, Ogawa, Yoshihiro
Format: Article
Language:English
Subjects:
Aldosterone
Angiotensin
Antihypertensives
Chronic myeloid leukemia
Enzyme inhibitors
Epidermal growth factor receptors
Glomerular filtration rate
Hematology
Hypertension
Imatinib
Inhibitors
Kinases
Leukemia
Medicine
Medicine & Public Health
Myeloid leukemia
Oncology
Original Article
Patients
Renin
Toxicity
Tyrosine
Tyrosine kinase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, TKI-related chronic renal toxicity has been reported, particularly in patients with hypertension. We assessed whether incidental use of specific types of antihypertensive drugs, including renin – aldosterone – angiotensin system inhibitors (RAASis), affects the change in estimated glomerular filtration rate (eGFR) during TKI treatment. We retrospectively analyzed all eGFR measurements during TKI treatment for 142 CML patients at Kyushu University Hospital, estimating the rate of eGFR change using a mixed-effects model. Overall, a significant interaction was found between the type of antihypertensive medication used and the yearly change in eGFR ( P  
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-022-03433-6